VanderLinden Ryan T, Hemmis Casey W, Yao Tingting, Robinson Howard, Hill Christopher P
From the Department of Biochemistry, University of Utah, Salt Lake City, Utah 84112.
the Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado 80523, and.
J Biol Chem. 2017 Jun 9;292(23):9493-9504. doi: 10.1074/jbc.M117.785287. Epub 2017 Apr 25.
The 26S proteasome is a large cellular assembly that mediates the selective degradation of proteins in the nucleus and cytosol and is an established target for anticancer therapeutics. Protein substrates are typically targeted to the proteasome through modification with a polyubiquitin chain, which can be recognized by several proteasome-associated ubiquitin receptors. One of these receptors, RPN13/ADRM1, is recruited to the proteasome through direct interaction with the large scaffolding protein RPN2 within the 19S regulatory particle. To better understand the interactions between RPN13, RPN2, and ubiquitin, we used human proteins to map the RPN13-binding epitope to the C-terminal 14 residues of RPN2, which, like ubiquitin, binds the N-terminal pleckstrin-like receptor of ubiquitin (PRU) domain of RPN13. We also report the crystal structures of the RPN13 PRU domain in complex with peptides corresponding to the RPN2 C terminus and ubiquitin. Through mutational analysis, we validated the RPN2-binding interface revealed by our structures and quantified binding interactions with surface plasmon resonance and fluorescence polarization. In contrast to a previous report, we find that RPN13 binds ubiquitin with an affinity similar to that of other proteasome-associated ubiquitin receptors and that RPN2, ubiquitin, and the deubiquitylase UCH37 bind to RPN13 with independent energetics. These findings provide a detailed characterization of interactions that are important for proteasome function, indicate ubiquitin affinities that are consistent with the role of RPN13 as a proteasomal ubiquitin receptor, and have major implications for the development of novel anticancer therapeutics.
26S蛋白酶体是一种大型细胞组件,介导细胞核和细胞质中蛋白质的选择性降解,是抗癌治疗的既定靶点。蛋白质底物通常通过多聚泛素链修饰而靶向蛋白酶体,多聚泛素链可被几种蛋白酶体相关的泛素受体识别。其中一种受体RPN13/ADRM1,通过与19S调节颗粒内的大型支架蛋白RPN2直接相互作用而被招募到蛋白酶体。为了更好地理解RPN13、RPN2和泛素之间的相互作用,我们使用人类蛋白质将RPN13结合表位定位到RPN2的C末端14个残基,该残基与泛素一样,结合RPN13的泛素N末端普列克底物蛋白样受体(PRU)结构域。我们还报告了RPN13 PRU结构域与对应于RPN2 C末端和泛素的肽形成复合物的晶体结构。通过突变分析,我们验证了我们的结构所揭示的RPN2结合界面,并用表面等离子体共振和荧光偏振定量了结合相互作用。与之前的一份报告相反,我们发现RPN13与泛素的结合亲和力与其他蛋白酶体相关泛素受体相似,并且RPN2、泛素和去泛素化酶UCH37以独立的能量学方式与RPN13结合。这些发现详细描述了对蛋白酶体功能很重要的相互作用,表明了与RPN13作为蛋白酶体泛素受体的作用一致的泛素亲和力,并且对新型抗癌治疗的开发具有重要意义。